Corin, the manufacturer of replacement hip and knee joints, says it has seen growth in all its markets except Australia and describes the start of the year as 'strong'.
Looking at the numbers you can see where its coming from: for the four months ended April 30th, constant currency sales growth was 10% excluding stocking orders.
The growth has been led by sales of new hip products. Knee sales, which have in recent years declined, were broadly flat while ligament reconstruction products have shown good growth in the UK, but have in aggregate declined on the back of weaker Australian sales.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
There has been double-digit sales growth in the UK, US, Japanese and German and Austrian markets, with only the Australian business declining compared to the prior year.
Initial implantations of the new "Unity Knee" have gone well and the product remains on track for commercial launch early in 2013.
Corin shares had risen 5.5% by 10:45.
BS
-
How Meta’s shares are thriving in adversity - will 'remarkable' streak continue?Despite big shake-ups to its Magnificent Seven colleagues, Meta’s shares have been on one of the best winning streaks in stock market history
-
How much stamp duty do you pay on buy-to-let properties?Stamp duty is an important cost to consider when buying property. We explain what rates landlords can expect to pay when purchasing a buy-to-let.
